- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03674840
Comparison of Optical Quality With Different Placement of Refractive Multifocal Intraocular Lens
August 3, 2022 updated by: Hong Qi, Peking University Third Hospital
The study aims to compare postoperative optical quality between two different implanting position of a rotationally asymmetric MIOL [SBL-3 Lenstec; +3.00 diopters (D)], angle kappa based implantation and 0 to 180 degree implantation, in order to find out the optimal implantation position for SBL-3.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
SBL-3 has been proved to provide patients with good near, intermediate and distant visual acuity, but there is not much study on the impact of SBL-3 position on postoperative visual acuity.The regional refractive design of SBL-3 means it could be affected by pupil center shift (described by angle kappa: the difference between visual axis and pupil axis), the investigators assume that maintaining the ideal ratio of distant and near segment(50% vs 42%) in the pupil center could yield both good distant and near postoperative visual acuity postoperatively.
Therefore, the investigators designed the implantation by placing the IOL based on angle kappa to make sure the ratio of distant and near segment exposure in the pupil center close to 50:42.
In this study, the investigators assessed the optical quality in patients with SBL-3 implantation based on angle kappa and 0 to 180 degree to provide surgeons with information for choosing appropriate implantation position for optimum postoperative satisfaction of SBL-3.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100191
- Peking University Third Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
54 years to 81 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age related cataract
- underwent bilateral cataract surgery and SBL-3 implantation
- corneal astigmatism <1.5D
Exclusion Criteria:
- patients with active ocular inflammation
- neuro-ophthalmic disease and macular disease
- previous corneal or intraocular surgery, corneal opacities or disease
- patients had surgical complications, pupillary trauma, inability to place the lens in the capsular bag
- IOL tilt or decentration deviated from intraoperative positioning
- difficulties with examinations and follow-up
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
OTHER: control group
Subjects in this group will go through a cataract surgery with SBL-3 implantation in the direction of 0 to 180 degree guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
|
SBL-3 implantation in the direction of 0 to 180 degree guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
|
|
EXPERIMENTAL: design group
Subjects in this group will go through a cataract surgery with SBL-3 implantation based on kappa angle(described by Pentacam HR preoperatively) guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
|
SBL-3 implantation based on kappa angle guided by Callisto Eye System(Carl Zeiss Meditec, Germany) intraoperatively.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Uncorrected visual acuity
Time Frame: 3 months postoperatively
|
Comparison of uncorrected distance visual acuity (UCVA), intermediate visual acuity, near visual acuity were measured at 5m, 80cm and 33cm respectively.
All visual acuity measurements were conducted under photopic conditions (85 cd/m2) and at 100% contrast in design group and control group.
|
3 months postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Optical quality
Time Frame: 3 months postoperatively
|
An OPD scan III aberrometer (NIDEK Co. Ltd., Gamagori, Japan) was used to evaluate postoperative mesopic and photopic pupil diameters and the quality of vision in each subject.
Visual acuity was evaluated by MTF(modulation transfer function), SR(strehl ratio), intraocular total aberration, high order aberration, spherical aberration, coma aberration, trefoil aberration under 4mm pupil diameter.
|
3 months postoperatively
|
|
Contrast sensitivity
Time Frame: 3 months postoperatively
|
Contrast sensitivity measures were conducted uniocularly, under photopic, mesopic (5 cd/m2), photopic with glare and mesopic with glare conditions, with the OPTEC 6500 contrast sensitivity test (Stereo Optical, USA).
Contrast sensitivity was evaluated at five spatial frequencies (1.5, 3, 6, 12, and 18 cycles per degree [cpd]).
Patients were allowed 5 minutes to adapt to each illumination level before testing.
|
3 months postoperatively
|
|
Defocus curve
Time Frame: 3 months postoperatively
|
Monocular defocus curves were obtained in all patients, positioned at 5m under photopic (>85 cd/m 2 ) condition to measure the visual acuity with each defocus lens, representing the consecutive visual function of each eye.
Negative lenses were added in 0.50 D steps and the visual acuity was recorded for each type of defocus level.
The procedure was then repeated but with positive lenses.
The range of defocus evaluated was from -4.00D to +2.00D.
|
3 months postoperatively
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Hong Qi, Peking University Third Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 12, 2017
Primary Completion (ACTUAL)
February 1, 2019
Study Completion (ACTUAL)
April 1, 2019
Study Registration Dates
First Submitted
September 13, 2018
First Submitted That Met QC Criteria
September 14, 2018
First Posted (ACTUAL)
September 18, 2018
Study Record Updates
Last Update Posted (ACTUAL)
August 5, 2022
Last Update Submitted That Met QC Criteria
August 3, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20180906
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cataract, Age-Related
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityNot yet recruiting
-
Sohag UniversityActive, not recruiting
-
Wenzhou Medical UniversityNot yet recruiting
-
Horizon Surgical Systems Inc.RecruitingCataract, Age-RelatedEl Salvador
-
Wenzhou Medical UniversityRecruiting
-
Sun Yat-sen UniversityRecruitingAge-related CataractChina
-
University Hospital, ToursCompletedAge-related CataractFrance
-
Wenzhou Medical UniversityUnknownAge-Related CataractChina
-
Sun Yat-sen UniversityCompleted
Clinical Trials on 0 to 180 degree SBL-3 implantation
-
Medtronic - MITGCompletedObesity | Breast PtosisUnited States, Germany
-
Instituto Nacional de Enfermedades RespiratoriasCompletedSleep | Decision Making | Internship and ResidencyMexico
-
University of California, San FranciscoNational Institute on Aging (NIA); Penn State University; Harvard UniversityCompletedStress | Depressive Symptoms | Psychological Distress | Psychological Stress | Signs and Symptoms | Psychological | Child MaltreatmentUnited States
-
University of AarhusOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruiting
-
Hospices Civils de LyonCompleted
-
Necmettin Erbakan UniversityActive, not recruitingPeriodontitis | MEDİTERRANEAN DİETTurkey
-
Assiut UniversityNot yet recruitingAdolescents | Psychiatric Disorders | Diabetes Mellitus Type 1
-
Nelson HamerschlakMiltenyi Biotec, Inc.RecruitingAcute Lymphoblastic Leukemia, in Relapse | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory | Acute Lymphoblastic Leukemia RefractoryBrazil
-
University Hospital, Clermont-FerrandRecruitingColon Neoplasm | Neuropathy;Peripheral | Cancer, LungFrance